Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: Results of a single-institutional phase II study-Reference-Cited by-同舟云学术

Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: Results of a single-institutional phase II study

Published:2009-08 Issue:2 Volume:114 Page:210-214
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Kang Heeseok,Kim Tae-Joong,Lee Yoo-Young,Choi Chel Hun,Lee Jeong-Won,Bae Duk-Soo,Kim Byoung-Gie

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference17 articles.

1. Relapsed ovarian cancer: challenges and management strategies for a chronic disease;Armstrong;Oncologist,2002

2. Emerging role of topotecan in front-line treatment of carcinoma of the ovary;Coleman;Oncologist,2002

3. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study;Creemers;J. Clin. Oncol.,1996

4. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;ten Bokkel Huinink;J. Clin. Oncol.,1997

5. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy;van der Zee;Cancer Res.,1991

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epithelial ovarian cancer;DiSaia and Creasman Clinical Gynecologic Oncology;2023

2. Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study;Journal of Gynecologic Oncology;2020

3. Epithelial Ovarian Cancer;Clinical Gynecologic Oncology;2018

4. Rapamycin-topotecan combination exhibited enhanced antitumor efficacy compared to topotecan used alone in cisplatin-resistant ovarian cancer cells;Neoplasma;2015

5. Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors;BMC Cancer;2012-09-11